1. Home
  2. CHMI vs LUNG Comparison

CHMI vs LUNG Comparison

Compare CHMI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cherry Hill Mortgage Investment Corporation

CHMI

Cherry Hill Mortgage Investment Corporation

HOLD

Current Price

$2.76

Market Cap

83.3M

Sector

Real Estate

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.87

Market Cap

82.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHMI
LUNG
Founded
2012
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Industrial Specialties
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
82.5M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
CHMI
LUNG
Price
$2.76
$1.87
Analyst Decision
Hold
Buy
Analyst Count
3
7
Target Price
$3.00
$6.81
AVG Volume (30 Days)
198.9K
348.1K
Earning Date
03-05-2026
02-18-2026
Dividend Yield
14.81%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$40,202,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
$31.73
$5.03
P/E Ratio
$144.11
N/A
Revenue Growth
N/A
15.59
52 Week Low
$2.17
$1.31
52 Week High
$3.68
$9.37

Technical Indicators

Market Signals
Indicator
CHMI
LUNG
Relative Strength Index (RSI) 59.78 41.57
Support Level $2.65 $1.68
Resistance Level $2.77 $1.96
Average True Range (ATR) 0.08 0.12
MACD 0.00 -0.04
Stochastic Oscillator 88.68 26.76

Price Performance

Historical Comparison
CHMI
LUNG

About CHMI Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: